Neurosense Therapeutics Ltd
General ticker "NRSN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $18.5M
Neurosense Therapeutics Ltd does not follow the US Stock Market performance with the rate: -3.6%.
Estimated limits based on current volatility of 12.0%: low 1.04$, high 1.33$
Factors to consider:
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [0.63$, 1.85$]
- 2023-12-31 to 2024-12-30 estimated range: [0.45$, 1.37$]
Short-term NRSN quotes
Long-term NRSN plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $2.89MM | $5.59MM | $13.55MM |
| Operating Income | $-2.89MM | $-5.59MM | $-13.55MM |
| Non-Operating Income | $0.06MM | $1.55MM | $1.21MM |
| Interest Expense | $0.00MM | $1.15MM | $0.01MM |
| R&D Expense | $2.50MM | $3.08MM | $6.42MM |
| Income(Loss) | $-2.83MM | $-4.04MM | $-12.34MM |
| Taxes | $0.00MM | $-1.55MM | $-1.14MM |
| Profit(Loss) | $-2.83MM | $-2.50MM | $-11.20MM |
| Stockholders Equity | $0.66MM | $9.01MM | $5.62MM |
| Inventory | $0.00MM | $0.18MM | $3.68MM |
| Assets | $0.78MM | $11.43MM | $7.71MM |
| Operating Cash Flow | $-0.69MM | $-1.54MM | $-7.59MM |
| Capital expenditure | $0.01MM | $0.02MM | $0.07MM |
| Investing Cash Flow | $-0.01MM | $-0.02MM | $-3.54MM |
| Financing Cash Flow | $0.51MM | $11.90MM | $3.69MM |
| Earnings Per Share* | $-1.46 | $-1.29 | $-0.97 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.